Picton Mahoney Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Picton Mahoney Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-15,950	Closed	-$504K	–	487
2023 Q3	$504K	Buy	15,950 +24	+0.2%	+$931	0.02%	237
2023 Q2	$649K	Buy	15,926 +16	+0.1%	+$649	0.03%	249
2023 Q1	$593K	Buy	15,910 +8	+0.1%	+$314	0.03%	301
2022 Q4	$555K	Buy	15,902 +500	+3%	+$23.8K	0.03%	401
2022 Q3	$862K	Buy	15,402 +1,323	+9%	+$82.1K	0.03%	456
2022 Q2	$730K	Buy	14,079 +1,672	+13%	+$84.9K	0.03%	571
2022 Q1	$904K	Buy	12,407 +6,977	+128%	+$591K	0.03%	584
2021 Q4	$643K	Sell	5,430 -1,020	-16%	-$128K	0.02%	633
2021 Q3	$864K	Hold	6,450	–	–	0.03%	558
2021 Q2	$1.05M	Buy	+6,450	New	+$502K	0.03%	511

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Picton Mahoney Asset Management's NTLA Position: Q4 2023 in Review

Picton Mahoney Asset Management sold out of Intellia Therapeutics (NTLA) in Q4 2023, closing a stake of 15,950 shares — an estimated $504K sold.

Picton Mahoney Asset Management first reported a position in NTLA in Q2 2021 and held it in 10 quarters. The position peaked at $1.05M in Q2 2021. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2023.

Picton Mahoney Asset Management reported no remaining Intellia Therapeutics position as of Q4 2023 after selling out during the quarter.
Picton Mahoney Asset Management sold 15,950 Intellia Therapeutics shares in Q4 2023, an estimated $504K.
Picton Mahoney Asset Management first reported a position in Intellia Therapeutics in Q2 2021 and held it in 10 quarters.
Picton Mahoney Asset Management's Intellia Therapeutics position peaked at $1.05M in Q2 2021.
293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2023.

Based on Picton Mahoney Asset Management's 13F filing for Q4 2023, filed 6 Feb 2024.